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Abstract
Introduction: Inflammation associated with synovial expression of TNFa is a recognised feature of osteoarthritis
(OA), although no studies have yet reported beneficial effects of anti-TNFa therapy on clinical manifestations of
inflammation in OA.
Methods: We conducted an open-label evaluation of adalimumab over 12 weeks in 20 patients with OA of the
knee and evidence of effusion clinically. Inclusion criteria included daily knee pain for the month preceding study
enrolment and a summed pain score of 125 to 400 mm visual analogue scale on the Western Ontario and
McMaster University Osteoarthritis Index (WOMAC) pain subscale. The primary outcome was the Osteoarthritis
Research Society International/Outcome Measures in Rheumatology Clinical Trials (OARSI/OMERACT) response
criterion at week 12. Secondary outcomes included the WOMAC pain score 20% and 50% improvement, WOMAC
stiffness and function scores, patient and physician global visual analogue scale, as well as target joint swelling.
Results: Treatment was well tolerated and completed by 17 patients with withdrawals unrelated to lack of efficacy
or adverse events. By intention to treat, an OARSI/OMERACT response was recorded in 14 (70%) patients. WOMAC
pain 20% and 50% responses were recorded in 14 (70%) patients and eight (40%) patients, respectively. Significant
improvement was observed in mean WOMAC pain, stiffness, function, physician and patient global, as well as
target joint swelling at 12 weeks (P < 0.0001 for all). After treatment discontinuation, 16 patients were available for
assessment at 22 weeks and OARSI/OMERACT response compared with baseline was still evident in 10 (50%)
patients.
Conclusion: Targeting TNFa may be of therapeutic benefit in OA and requires further evaluation in controlled
trials.
Trial registration: ClinicalTrials.gov: NCT00686439.
Introduction
Osteoarthritis (OA) is the most common form of arthri-
tis, involving approximately 10% of Canadians [1]. The
disease is characterised by disruption of chondrocyte
homeostasis with the balance being shifted toward tissue
degradation, leading to the progressive loss of cartilage
extracellular matrix. Although often considered a non-
inflammatory arthropathy, the results of more recent
studies indicate that cytokine and growth factor produc-
tion is increased in all three joint components; namely,
the synovial membrane, cartilage, and subchondral bone
[2,3]. Among these factors, the cytokines TNF, IL-1, IL-6,
and IL-17 seem most involved in the process of cartilage
destruction [2,4], while cartilage repair that could restore
the functional integrity of the joint is impaired because
chondrocytes appear unable to respond to insulin-like
growth factor-1 or respond abnormally to transforming
growth factor-beta - growth factors that also modulate
cytokine expression [2]. In addition, synovial inflamma-
tion is frequently evident in OA patients using magnetic
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resonance imaging (MRI) and has been associated with
pain [5,6]. Arthroscopic studies suggest that localised
proliferative and inflammatory changes of the synovium
occur in up to 50% of OA patients, and the activated
synovium may produce proteases and cytokines that
accelerate progression of disease [7]. OA synovial macro-
phages exhibit an activated phenotype, as demonstrated
by the production of both proinflammatory cytokines,
such as IL-1 and TNF, and vascular endothelial growth
factor [8-10].
To date, no specific therapy based on fundamental
intracellular pathways of chondrocytes exists for the
medical management of OA with the exception of anti-
inflammatory corticosteroids and NSAIDs. However, our
increased understanding of the molecular mechanisms
underlying the degenerative process in OA has led to a
possible targeted therapeutic approach to the manage-
ment of the disease. Among the factors so far identified,
TNF has received particular attention because of its pre-
dominance in the pathogenesis of other arthritic diseases.
Results from one study showed that PEGylated soluble
TNF receptor 1, an antagonist of TNF, inhibited both the
increase in type II collagen cleavage by collagenase and
the increase in glycosaminoglycan release observed in
explant cultures of osteoarthritic articular cartilage [11].
Furthermore, PEGylated soluble TNF receptor 1, either
alone or in combination with anakinra, an IL-1 receptor
antagonist, frequently downregulated gene expression of
matrix metalloproteases MMP1, MMP3 and MMP13
that are involved in cartilage extracellular matrix degra-
dation. Conversely, PEGylated soluble TNF receptor 1
and anakinra upregulated aggrecan and type II collagen
gene expression in about 50% of OA cartilage explant
cultures. These findings suggest that inhibition of TNF
may offer a useful therapeutic approach to the manage-
ment of OA.
The present study was designed to provide preliminary
evidence for the clinical efficacy and safety of the TNFa
antagonist adalimumab in subjects with OA of the knee
and inflammatory manifestations evident as joint effusion
on clinical examination, whose pain persists despite max-
imum tolerated doses of conventional therapy.
Materials and methods
Patient population
This open-label trial of adalimumab was performed in
patients ≥ 40 years of age with inflammatory OA of the
knee. Patients had a diagnosis of OA of the index knee
according to American College of Rheumatology cri-
teria, including radiological evidence of OA (Kellgren-
Lawrence grade 2 or grade 3) [12]. Inclusion criteria
included continual pain for at least 6 months prior to
inclusion in the study with daily knee pain in the month
preceding study enrolment, and pain that persisted
despite conventional treatment defined as any one of
the following medications taken daily during any one of
the preceding 6 months: acetaminophen (2 to 4 g/day),
maximum tolerated and recommended doses of an
NSAID, or acetaminophen/codeine combination (that is,
Tylenol 2, 3, and 4;) taken at least three times daily.
Patients had to have a summed pain score of 125 to
400 mm (visual analogue scale (VAS)) on the WOMAC
pain subscale in the index (more symptomatic) knee,
and the analgesic/NSAID dosage had to have been
stable for 2 weeks prior to enrolment in the study, with
concomitant use of NSAIDs permitted at stable doses
during the study. Those patients receiving analgesic
therapy were instructed to take stable doses in the
24 hours prior to each study assessment. Patients had to
have clinical evidence of a knee effusion in the index
(more symptomatic) knee at screening and at baseline.
The study received local institutional review board
approval from the University of Alberta Health Ethics
Review Board and all patients provided written informed
consent prior to participation.
Patients were excluded if they had evidence of an
autoimmune cause of arthritis, clinically significant med-
ical conditions including active infection, predominant
patellofemoral disease, a concurrent medical or arthritic
condition that could confound evaluation of the index
joint (for example, post-traumatic or any secondary
form of knee OA), a history of clinically significant
trauma, surgery or diagnostic arthroscopy to the index
knee, intra-articular injections of steroid and/or hyaluro-
nate compounds into the index knee within 3 months of
study enrolment, were in the upper tertile of the age-
adjusted and race-adjusted norms for body mass index,
and had a history of cancer or lymphoproliferative
disease.
Study procedures
Prior to study enrolment, each patient underwent a clini-
cal evaluation including medical history, physical examina-
tion, laboratory studies, purified protein derivative skin
test, chest X-ray, and a review of concurrent medications.
Laboratory tests required for eligibility included a negative
serum and urine pregnancy test, hepatitis B surface anti-
gen, anti-hepatitis C antibody, and normal complete blood
count, alanine aminotransferase, and serum creatinine.
Patients received six biweekly subcutaneous injections of
40 mg adalimumab over 12 weeks. Patients were assessed
at baseline and at weeks 4, 8, and 12 of treatment. Evalua-
tions at each visit included the WOMAC (Likert 1 to 5
scale) [13], physician and patient assessments of global dis-
ease activity by 100 mm VAS score, target joint assess-
ment for tenderness and swelling (0 to 3 scale for both),
and self-reported expanded target joint assessment (1 to 5
scale) focused on impairment of activity and sleep [14].
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All patients underwent a final efficacy and safety assess-
ment at week 22.
Outcome measures
The primary endpoint was the number (percentage) of
patients achieving an Osteoarthritis Research Society
International/Outcome Measures in Rheumatology Clini-
cal Trials (OARSI/OMERACT) response at week 12 [15].
This is defined as an improvement in pain or function of
at least 50% and a decrease of at least 20 mm on the VAS
for pain or function, or occurrence of at least two of the
following: decrease in pain of at least 20% and at least
10 mm on the VAS; improvement in function of at least
20% and a decrease of at least 10 mm on the VAS; and an
increase in the patient’s global assessment score by at least
20% and at least 10 mm on the VAS. Secondary endpoints
included change in the WOMAC pain subscale score,
WOMAC pain subscale 20% and 50% improvement,
change in the WOMAC stiffness and function subscales,
change in the patient and physician global assessment of
disease status score, change in the target joint tenderness
and swelling score, and change in self-reported activity
and sleep impairment score from baseline to week 12.
Statistical analysis
Because this was an uncontrolled open-label pilot study,
analyses were primarily descriptive. Analysis was based on
intention to treat. The proportion of patients achieving an
OARSI/OMERACT response was calculated for each time
point. Response was calculated according to an intent-to-
treat analysis. Comparisons of each clinical measure were
made between weeks 12 and baseline using Student t tests.
A last-observation-carried-forward analysis was used for
patients that did not complete the 12-week study.
Results
Patient population
The study population was typical of an OA population. No
unexpected concomitant diseases, presenting baseline dis-
ease characteristics, or prior/concomitant therapies were
noted. Almost all subjects were white Caucasians (19/20)
except for one (categorised as other). There were nine
males and 11 females of mean ± standard deviation (SD)
(median, range) age 57.3 ± 9.2 (55, 46 to 77) years. Mean ±
SD symptom duration was 4.7 ± 4.0 years, height was
168.8 ± 9.5 cm and weight was 83.5 ± 19.6 kg. Eleven
patients had never smoked, five were ex-smokers, and four
were current smokers. Nonsteroidal anti-inflammatory
agents were taken by 15 patients at screening and baseline
(diclofenac n = 5, ibuprofen n = 4, celecoxib n = 3,
naproxen n = 3), acetaminophen by 14 patients, codeine by
four patients, and tramadol by one patient. The target
joint was the right knee for 12 patients and the left knee
for eight patients. The Kellgren-Lawrence grade on
radiography was grade 3 for 13 patients and grade 2 for
seven patients. Eleven patients had previously had joint
aspiration and intra-articular injection with corticosteroids.
None of these had crystals detected. At screening, the
mean ± SD summed WOMAC pain score was 299.5 ±
69.4 and the median (range) was 292 (171 to 445). The
mean ± SD WOMAC pain subscale score was 59.9 ± 13.9
and the median (range) WOMAC pain score was 58.4
(34.2 to 89.0). A summary of disease duration and charac-
teristics at baseline for all subjects treated with any dose of
adalimumab is presented in Table 1.
Clinical efficacy
Primary endpoint
At 12 weeks, 14 (70%) patients had achieved an OARSI/
OMERACT response by intent-to-treat analysis. This
response was observed at 4 and 8 weeks in nine (45%)
patients and 14 (70%) patients, respectively. Treatment
Table 1 Baseline disease characteristics
Duration of osteoarthritis (years)
Mean (standard deviation) 4.7 (4.0)
Median 2.5
Minimum-maximum 1 to 15
WOMAC pain (0 to 100)
Mean (standard deviation) 60.78 (17.51)
Median 59.00
Minimum-maximum 28.80 to 88.20
WOMAC stiffness (0 to 100)
Mean (standard deviation) 69.70 (16.27)
Median 75.00
Minimum-maximum 27.50 to 92.50
WOMAC function (0 to 100)
Mean (standard deviation) 66.00 (19.36)
Median 65.50
Minimum-maximum 26.06 to 95.63
Patient global (0 to 100)
Mean (standard deviation) 60.55 (21.96)
Median 61.00
Minimum-maximum 16.00 to 92.00
Joint tenderness (0 to 3)
Mean (standard deviation) 1.75 (0.44)
Median 2.00
Minimum-maximum 1.00 to 2.00
Joint swelling (0 to 3)
Mean (standard deviation) 2.15 (0.37)
Median 2.00
Minimum-maximum 2.00 to 3.00
Physician global (0 to 100)
Mean (standard deviation) 69.65 (12.74)
Median 67.50
Minimum-maximum 46.00 to 95.00
WOMAC, Western Ontario and McMaster University Osteoarthritis Index.
Maksymowych et al. Arthritis Research & Therapy 2012, 14:R206
http://arthritis-research.com/content/14/5/R206
Page 3 of 7
was discontinued at 12 weeks and patients were reas-
sessed at week 22. Four patients were not available for
the 22-week follow-up having discontinued from the
study by 12 weeks. Two of these patients had an
OARSI/OMERACT response at 12 weeks but had dis-
continued the study, due to a flare of interstitial colitis
in one patient, after having received two doses of adali-
mumab, and the other relocating out of the country
after having received all doses of adalimumab. A third
patient moved away from the study site after having
received two doses of adalimumab and had not achieved
an OARSI/OMERACT response at 12 weeks. A fourth
patient received only one dose of study drug and had
not achieved an OARSI/OMERACT response at
12 weeks. Of the 16 patients who completed 12 weeks
of treatment and follow-up there were only two patients
who had a numerically worse WOMAC pain subscale
score at week 12 compared with baseline, and in neither
was the increase greater than 10%. An OARSI/OMER-
ACT response was observed in 13 (65%) patients at 22
weeks. Of these, 10 (50%) patients had an OARSI/
OMERACT response that was evident at both 12 and
22 weeks and three (15%) patients had an OARSI/
OMERACT response at 22 weeks but not at 12 weeks.
Two (10%) patients had an OARSI/OMERACT response
at 12 weeks that was no longer evident at 22 weeks.
Secondary endpoints
A significant reduction was observed in WOMAC pain,
stiffness, and function subscales at week 12 (Table 2).
All three subscale scores were significantly lower at 8
weeks (P < 0.0001). The number (%) of patients who
reported a reduction ≥ 20% and ≥ 50% in the WOMAC
pain subscale score was 14 (70%) and eight (40%) using
last-observation-carried-forward data.
A significant reduction from baseline was observed in
patient and physician global assessments at week 12 (P <
0.0001), and this was already evident by week 4 (P = 0.016
and P < 0.0001 for patient and physician global, respec-
tively) and week 8 (P < 0.0001 for both) (Table 3).
A significant reduction from baseline was observed in
self-reported activity at week 12 (P = 0.0025) (Table 3).
This was already evident by 8 weeks (P = 0.0008). A sig-
nificant reduction from baseline was observed in self-
reported impairment of sleep at week 12 (P = 0.003)
(Table 3). This was already evident by 8 weeks (P =
0.0008).
A significant reduction from baseline was observed in
assessor evaluation of target joint tenderness at week 12
(P = 0.002) (Table 3). This was already evident by 8
weeks (P = 0.0004). A significant reduction from baseline
was observed in assessor evaluation of target joint swel-
ling at week 12 (P = 0.0005) (Table 3). This was already
evident by 4 weeks (P = 0.0009) and 8 weeks (P <
0.0001). Of particular note, three patients had swelling
evident at 12 weeks that was no longer evident on physi-
cal examination at 22 weeks (two patients with grade 2
swelling and one patient with grade 3 swelling).
Safety
Adverse events were minor with no serious events being
recorded. One patient required oral steroid for micro-
scopic interstitial colitis after having received two doses
of adalimumab. This was a pre-existing condition that
was stable at baseline without requirement for any con-
comitant medication. The patient was withdrawn from
the study at week 8.
Discussion and conclusion
The results from this 12-week open-label study demon-
strated that adalimumab seems effective in reducing the
signs and symptoms of inflammatory OA of the knee. An
OARSI/OMERACT response was observed in the major-
ity (70%) of patients, and 40% of patients had a major
response as defined by WOMAC pain subscale improve-
ment ≥ 50%. All secondary variables also demonstrated
significant improvement from baseline that was often
observed by 8 weeks. The response was also maintained
in most patients at the last time of follow-up at 22 weeks
after treatment had been discontinued for 10 weeks. In a
few patients the response was delayed and was not evi-
dent at 12 weeks but became apparent at 22 weeks. Of
particular note, three patients had substantial swelling
evident at 12 weeks that was no longer evident on physi-
cal examination at 22 weeks. This suggests that a period
> 12 weeks may be preferable for a double-blind study.
The objective of this study was to obtain preliminary evi-
dence that an anti-TNFa strategy might have clinical bene-
fit in patients with clinically apparent inflammatory OA.
Table 2 WOMAC subscales in patients with inflammatory osteoarthritis of the knee who received open-label
adalimumab
Baseline 4 weeks 8 weeks 12 weeks P valuea 22 weeksb
WOMAC pain 60.8 (17.5) 49.6 (21.0) 40.2 (23.4) 36.1 (23.6) < 0.0001 41.5 (18.9)
WOMAC stiffness 69.7 (16.3) 58.5 (18.3) 44.1 (26.0) 37.0 (25.1) < 0.0001 48.6 (20.1)
WOMAC function 66.0 (19.4) 53.2 (20.3) 41.1 (25.8) 39.2 (25.1) < 0.0001 46.6 (21.3)
Mean (standard deviation) for Western Ontario and McMaster University Osteoarthritis Index (WOMAC) subscales over 22 weeks in 20 patients with inflammatory
osteoarthritis of the knee who received open-label adalimumab for 12 weeks. aWeek 12 data versus baseline according to paired t test using last-observation-
carried-forward data. bWeek 22 data are based on 16 patients who attended for assessment.
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Many patients were not taking maximum doses of NSAID
and none were taking acetaminophen 4 g/day as recom-
mended in treatment guidelines either because of lack of
tolerability or because of lack of efficacy. The majority had
also failed intra-articular steroids. We excluded patients
who were in the upper tertile of the age-adjusted and race-
adjusted norms for body mass index. Our patients there-
fore reflect a treatment-refractory group of patients and
highlight the limited therapeutic options that are currently
available. In cross-sectional studies of MRI in knee OA,
knee effusions and synovitis have been shown to be more
often present in persons with knee pain than in persons
with a comparable amount of radiographic knee OA but
without pain [16-19]. Synovial thickening seen on noncon-
trast-enhanced MRI in the infrapatellar region of knees
with OA has shown low-grade synovial inflammation on
biopsy and this feature was present in 73% of knees with
early OA [20]. Follow-up of patients with symptomatic
knee OA in the Boston Osteoarthritis of the Knee Study
has shown that change in synovitis correlated with change
in knee pain [21].
Other studies have also focused on targeting synovial
inflammation in patients with knee OA for symptomatic
relief. In addition to intra-articular steroids [22,23], one
study suggested that intra-articular anakinra (IL-1 receptor
antagonist) given to seven patients with knee OA resulted
in improvement in pain that paralleled improvements in
MRI synovial scores [24]. These studies, along with our
observation that targeting anti-TNFamay be clinically ben-
eficial, suggest that synovitis ought to be an important
treatment target in patients with OA. A recent double-
blind, placebo-controlled study could demonstrate no
improvement from baseline to week 4 in knee OA symp-
toms after a single intra-articular injection of anakinra [25].
Serum anakinra concentrations were below the quantifica-
tion limit 24 hours post dose for all patients, suggesting
that there is no depot effect from intra-articular injection of
anakinra and that repeat injection may be necessary.
To date there has been a paucity of studies on anti-
TNFa agents in OA. Recently, however, one study
reported findings of a pilot study of adalimumab in OA of
the hands [26]. In this open-label study, 12 patients aged >
45 years with erosive/inflammatory OA of the hands
defined by ≥ 2 tender and ≥ 2 swollen joints (distal inter-
phalangeal, proximal interphalangeal, first carpometacar-
pal) despite NSAIDs were treated with adalimumab 40 mg
every other week for 12 weeks. At the end of treatment, a
statistically significant improvement in the number of
swollen joints compared with baseline (P < 0.01) was
observed. Although there were no statistically significant
changes from baseline in the other efficacy measures,
trends suggested modest improvements and individual
patients had some benefit from treatment with adalimu-
mab. Of more direct relevance to the present study is a
published case report where adalimumab was used to treat
severe OA of the knee [27]. The administration of adali-
mumab was associated with a decrease in nocturnal pain.
After a second injection 2 weeks later, nocturnal pain in
the patient’s knee completely resolved. MRI analyses per-
formed 6 months after initiation of a treatment regimen
tailored to the patient’s needs (40 mg every 3 to 6 weeks)
indicated that adalimumab therapy decreased synovial
effusions, synovitis and bone marrow oedema. This is of
importance since the prevalence and size of bone marrow
lesions have been shown to be predictive of cartilage
damage [28]. In addition, bone marrow lesions have been
associated with the severity of pain perceived by the
patient [29,30]. Taken together, our data are consistent in
suggesting that TNFa inhibition could significantly
improve the condition of patients with severe OA particu-
larly when accompanied by inflammatory features.
There were several limitations to our study. Since this
was intended to be a proof-of-concept study, we were
limited in sample size and an assessment of predictors of
response was not feasible. We limited our analysis to a
subgroup of patients with clinical evidence of inflamma-
tion that did not include the most overweight patients
often seen in OA. Consequently, our results may not be
generalisable to the broader category of patients with
OA. The lack of a control group and an independent
assessor hindered the ability to discriminate placebo
effects from true therapeutic effects. Stable background
Table 3 Secondary endpoints in patients with inflammatory osteoarthritis of the knee who received open-label
adalimumab
Baseline 4 weeks 8 weeks 12 weeksa 22 weeksb
Patient global 60.6 (22.0) 49.7 (22.1)** 37.4 (22.6)* 36.1 (21.9)* 44.4 (22.5)
Physician global 69.7 (12.7) 44.6 (17.8)* 34.5 (16.9)* 40.7 (22.0)* 40.1 (25.3)
Activity impairment 6.30 (1.17) 5.70 (1.53) 4.90 (1.59)** 5.10 (2.00)* 5.19 (1.80)
Sleep impairment 2.90 (0.64) 2.35 (0.81) 2.10 (0.72)** 2.05 (0.89)** 2.50 (0.73)
Target joint tenderness 1.75 (0.44) 1.00 (0.73) 0.95 (0.69)** 0.95 (0.94)** 0.81 (75)
Target joint swelling 2.15 (0.37) 1.45 (0.89)** 1.00 (1.03)* 1.15 (1.14)** 0.75 (0.77)
Mean (standard deviation) values for secondary endpoints over 22 weeks in 20 patients with inflammatory osteoarthritis of the knee who received open-label
adalimumab for 12 weeks. aWeek 12 data versus baseline according to paired t test using last-observation-carried-forward data. bWeek 22 data are based on 16
patients who attended for assessment. *P < 0.0001, **P < 0.05.
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use of NSAIDs was allowed and, as the dose was kept
stable, should not have interfered with the clinical assess-
ments. The duration of our study was short, and there
was evidence in some patients that a longer course of
treatment might have been beneficial, but we chose 3
months of treatment since responders to adalimumab in
rheumatoid arthritis trials achieved a clinical response by
12 weeks. Our data showed that clinical responses were
sustained in the majority of patients at 22 weeks, which
was 10 weeks after treatment discontinuation. This sug-
gests that future trials should also incorporate a treat-
ment withdrawal design to determine whether a strategy
of pulse dosing might be effective for symptomatic con-
trol. This is particularly relevant in view of the costs of
treatment and the high frequency of OA in the popula-
tion. The design of future trials will also need to address
the high placebo response rates noted in previous studies,
particularly those evaluating intra-articular therapies and
glucosamine and chondroitin sulphate [25,31]. This may
reflect expectation bias for invasive therapies or therapies
already in widespread use and will require more complex
study designs that include objective parameters of inflam-
mation as well as cross-over designs.
In summary, short-term treatment with adalimumab
for 12 weeks in patients with inflammatory OA of the
knee refractory to conventional treatment resulted in
clinical benefit in the majority of patients using the
OARSI/OMERACT responder index. Major clinical
improvement was seen in almost one-half of the patients
that included improvement in function, daily activity, and
sleep in addition to objective amelioration of joint effu-
sion. A future long-term randomised, placebo-controlled
study is now warranted and should examine the effects of
treatment over a longer time frame and the sustainability
of clinical response after treatment discontinuation.
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